Korea Takes Its First Step Reimbursing IO Drugs
Executive Summary
Amid repeated calls industry, South Korea decides to pay for Keytruda and Opdivo in its first reimbursement of immuno-oncology drugs, albeit at limited scope. The government is poised to expand reimbursement of IO drugs going forward amid its plan to significantly expand health insurance coverage.
You may also be interested in...
MSD Exec On Progress, Complexity Of HTA For Keytruda In Asia-Pacific
MSD’s Global Medical Affairs Lead, Asia Pacific, Aileen Dualan, discusses in an interview with Scrip the diverse, multi-faceted HTA and reimbursement landscape for cancer therapies like Keytruda in the APAC region and progress made, among other issues.
Korea Signals Continued Policy Support For Pharma In 2018
Despite the regime change, South Korea remained generally supportive of the pharma and biotech industry in 2017. With comprehensive long-term plans proposed to nurture these sectors, the government appears poised to pursue its favorable stance towards industry in the coming year.
Tagrisso Reimbursed In Korea, After Difficult Price Negotiations
Korea's National Health Insurance Service and AstraZeneca reach an agreement on reimbursement of Tagrisso, sharply reducing financial burdens of NSCLC patients in the country. Tough price negotiations between the two sides underlines the difficulties pricey innovative drugs face to get reimbursed in the country.